Your Messages Inbox
Your Article Summary
See Latest ArticlesForest Announces Phase IIb Study Results For Oglemilast in Chronic Obstructive Pulmonary Disease
Forest Laboratories, 08/20/09
Forest Laboratories, Inc. and Glenmark Pharmaceuticals S.A. , a wholly owned subsidiary of Glenmark Pharmaceuticals India announced top–line results from a Phase IIb dose range–finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease. Once–daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Article Search
Sponsor